Cannabis Stocks Today 16 Nov 2026: Aurora sits at $4.94

Cannabis stocks mostly declined, with 24 of 35 tracked tickers falling. Aurora Cannabis (ACB) dropped 1.00% to $4.94, below takeover offers from Organigram (OGI) and Curaleaf (CURLF). MSOS ETF fell 3.63% to $3.72. Curaleaf reported Q3 revenue of $353M, up 11%. Glass House (GLASF) and Vext Science (VEXTF) saw steep declines.

Original reporting
Published Nov 17, 2026, 10:02 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 10:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Cannabis Stocks Today 16 Nov 2026: Aurora sits at $4.94 — source image
Decision brief

The 30-second read

$ACBNeutralLow
01

Why it matters

The only clearly decision-relevant thread is the Aurora acquisition contest (Organigram bid, Curaleaf competitive bid, and the 4 December expiry), while most other quoted moves are not tied to new disclosures.

02

Market read

Traders can monitor the Aurora bid contest for spread changes, but the rest of the tape is largely descriptive without fresh catalysts.

03

What to watch

The article emphasizes that several moves lack sourced catalysts; traders may need to check for late filings, deal-spread changes, or liquidity/OTC microstructure before assigning fundamental meaning.

Relevance 4/10Novelty 3/10Timing: pre-market US session, early-week cannabis tape weakness

Background

This is a multi-name cannabis market wrap with early-week pre-market weakness and a focus on Aurora’s M&A situation amid competing bids.

Company-level read

Ticker impact

$ACBNeutralMedium confidence
Context

Aurora Cannabis is the article’s named focus, trading at $4.94 down 1.00%, and is tied to Organigram’s $7.80/share buy offer.

Expected impact

Likely range-bound to slightly pressured as traders weigh bid certainty versus deal risk.

Evidence & confidence

The text links ACB to an agreed acquisition price and notes the offer is below the headline value, implying spread compression or widening can drive near-term moves.

$OGINeutralMedium confidence
Context

Organigram is a named acquirer in the deal, trading at $0.8286 down 0.65% after agreeing to buy Aurora for C$7.80/share.

Expected impact

Likely modest downside or volatility as deal execution risk is repriced.

Evidence & confidence

The article provides the agreed bid price and notes competition clearances for Curaleaf’s rival offer, which can affect perceived odds for OGI’s transaction.

$CURLFNeutralMedium confidence
Context

Curaleaf is central to the competitive bid, trading at $7.85 down 2.61%, with CEO commentary that it could raise its Aurora bid with due diligence access.

Expected impact

Likely choppy, with downside risk if traders think Curaleaf will not improve terms before the 4 December expiry.

Evidence & confidence

The article ties Curaleaf’s offer mechanics to Aurora holders and states the rival offer’s competition clearances and expiry date, both of which can drive bid-spread repricing.

$MSOSBearishHigh confidence
Context

The AdvisorShares Pure US Cannabis ETF (MSOS) is explicitly quoted at $3.72, down 3.63%, reflecting broad cannabis weakness in early trading.

Expected impact

Likely continued pressure if pre-market weakness persists and flows remain risk-off.

Evidence & confidence

The article directly reports MSOS’s current move and frames it as part of a broad decline across cannabis-linked tickers.

$VFFBearishMedium confidence
Context

Village Farms (VFF) is down 4.72% to $2.42, with the article stating no fresh disclosure explains the current level after its 9 November 8-K.

Expected impact

Likely range-bound to slightly lower as traders fade the lack of incremental news.

Evidence & confidence

The article explicitly says no fresh disclosure accounts for the current level, implying the move is not tied to a new fundamental datapoint.

Market effects

Broad cannabis-linked weakness suggests sector-wide risk-off and can widen bid spreads in M&A-linked names.

US pre-market weakness may spill into Canadian-listed cannabis sentiment at the open.

Limited direct global catalyst; mainly reflects North American cannabis tape and deal spread dynamics.

Counterpoint

Some of the biggest losers (especially OTC names) may be liquidity or stale-quote effects rather than new fundamental deterioration.

Key entities

  • Aurora Cannabis

    Subject of the article, trading at $4.94 and linked to an agreed acquisition by Organigram.

  • Organigram

    Acquirer in the Aurora deal, trading at $0.8286 after agreeing to buy Aurora for C$7.80/share.

  • Curaleaf Holdings

    Competitive bidder for Aurora, trading at $7.85, with CEO indicating it could raise its bid with due diligence access.

  • AdvisorShares Pure US Cannabis ETF

    MSOS quoted down 3.63%, signaling broad sector weakness.

Related articles

$CURLFHighAI 8/10

Curaleaf Holdings, Inc. Investor Relations Curaleaf Receives All Required Competition Law Clearances for Proposed Acquisition of Aurora Cannabis

Curaleaf Holdings, Inc. (CURLF) filed an SEC Form 8-K — Other Events. Curaleaf Holdings, Inc. Investor Relations Curaleaf Receives All Required Competition Law Clearances for Proposed Acquisition of Aurora Cannabis STAMFORD, Conn., Nov. 10, 2026 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (the "Company"), a leading internatio